New drug buntanetap tested for Long-Term safety in Parkinson's patients
Disease control
Recruiting now
This study is testing the long-term safety of a daily drug called buntanetap in 500 people with Parkinson's disease over 36 months. It includes two groups: those who have taken buntanetap before and those who have a deep brain stimulation device. The main goal is to see if the dr…
Phase: PHASE2, PHASE3 • Sponsor: Annovis Bio Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC